SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS

Marla C. Dubinsky  ¹     MIn A. Yang  ²     Mirko Fillbrunn  ²     Silvio Danese  ³     Johan Burisch  ⁴     Satoshi Tanida  ⁵     Dolly Sharma  ⁶     Dapo Ilo  ⁶     Wen Zhou  ⁶     Yuri Sanchez Gonzalez  ⁶     Laurent Peyrin-Biroulet  ^7    
1 Ichan School of Medicine, Mount Sinai, New York, United States
² Analysis Group, Inc., Boston, United States
³ IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
⁴ Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark
⁵ Education and Research Center for Community Medicine, Nagoya City University, Nagoya, Japan
⁶ AbbVie, Inc., North Chicago, United States
⁷ University Hospital of Nancy, Lorraine University, Vandoeuvre, France

Session
Patient reported outcomes in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)